Clinical Trial

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed/refractory autoimmune diseases.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-23; most recent amendment 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2025-12-09
Trial Details
NCT Number NCT07095075
Lead Sponsor Nanjing Legend Biotech Co.
Conditions Relapsed/Refractory Autoimmune Diseases
Enrollment 36 participants
Start Date 2025-10-14
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-10